Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Role of cachexia in advanced non-small cell lung cancer patients treated with EGFR-TKIS.

BMC cancer - 2 Apr 2026

Turcott Jenny G, Palomares-Palomares Cittim B, Rios-Garcia Eduardo, Cardenas-Fernandez Daniela, Diaz-Garcia Diego A, Torres Salvador Gutiérrez, Cardona Andrés F, Arrieta Oscar

Abstract excerpt

INTRODUCTION: Cachexia is a multifactorial syndrome associated with impaired physiologic reserve and adverse outcomes in advanced NSCLC. Its relationship with early toxicity and survival during EGFR-tyrosine kinase inhibitor (EGFR-TKI) therapy remains insufficiently characterized. We evaluated the impact of baseline cachexia on toxicity and clinical outcomes in patients with EGFR-mutated stage III–IV NSCLC...

Topics

Join the communities discussing this publication.

Aged
Aged, 80 and over
Cachexia
Carcinoma, Non-Small-Cell Lung
ErbB Receptors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Neoplasm Staging

Protein Kinase Inhibitors

Source

Open in PubMed Open full text

Identifiers

PMID: 41928147
DOI: 10.1186/s12885-026-15773-1
PMCID: PMC13188429

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Role of cachexia in advanced non-small cell lung cancer patients treated with EGFR-TKIS.PMID 41928147Read ↗

Cancer Cachexia Predicts Benefit of Immunotherapy Plus Chemotherapy in EGFR-mutant NSCLC After TKI Resistance.Semantic proximity Read ↗

Characterization of pretreatment cachexia through cytokine and nutritional analysis in lung cancer: the Marató cohortSemantic proximity Read ↗

Baseline anemia predicts a poor prognosis in patients with non-small cell lung cancer with epidermal growth factor receptor mutations: a retrospective study.Semantic proximity Read ↗

An analysis of the relationship between metastases and cachexia in lung cancer patients.Semantic proximity Read ↗

Nutritional status in the era of target therapy: poor nutrition is a prognostic factor in non-small cell lung cancer with activating epidermal growth factor receptor mutations.Semantic proximity Read ↗

Pathological features of tissues and cell populations during cancer cachexiaSemantic proximity Read ↗

A health-system-scale, episode-resolved multimodal atlas of cancer cachexiaSemantic proximity Read ↗

Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicity.Semantic proximity Read ↗

Platelet/lymphocyte ratio is a significant prognostic factor for targeted therapy in patients with EGFR-mutated non-small-cell lung cancer.Semantic proximity Read ↗

Discovery of distinct cancer cachexia phenotypes using an unsupervised machine-learning algorithm.Semantic proximity Read ↗

Significance of neutrophil-to-lymphocyte ratio in Western advanced EGFR-mutated non-small cell lung cancer receiving a targeted therapy.Semantic proximity Read ↗

Dynamic liver dysfunction predicts poor survival in patients with EGFR-mutant non-small cell lung cancer and liver metastases treated with EGFR tyrosine kinase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.